A Study to Establish the Diagnostic Value of the EPISEEK-MPE Liquid Biopsy Assay to Identify Cancer in Pleural Effusion Samples. (EPISEEK-MPE)
Development of a Molecular Assay to Diagnose Malignant Pleural Effusions
The goal of this study is to evaluate the EPISEEK-MPE laboratory test for diagnosis of malignant (cancerous) pleural effusions verses pleural effusions caused by a non-cancer condition. The study uses excess samples drained from around the lung as part of a patient's regular care. The main questions the study aims to answer are:
- Is the EPISEEK-MPE test reliable to detect cancer cells and aid in the diagnosis of malignant pleural effusions?
- Do age, race, gender and ethnicity change the reliability of the EPISEEK-MPE test?
- Can the results of the EPISEEK-MPE test predict which patients have a better chance of survival than others?
Participants will be asked to donate a small portion of the excess fluid drained from around the lung for research. Participants will also give permission to collect data from the medical records.
Visão geral do estudo
Status
Condições
Descrição detalhada
In clinical practice, it remains a challenge to distinguish between malignant pleural effusion (MPE) and benign pleural effusion (BPE). Because of the limitations of conventional cytology methods, there is an urgent need to develop a more accurate and effective method for the efficient diagnosis of MPE. In collaboration with the University of Arizona, Precision Epigenomics has developed the EPISEEK-MPE test that has the potential to be an effective complimentary tool for cytology in the process of differential diagnosis. The aim of this project is to conduct a multi-site clinical validation study to establish the EPISEEK-MPE test as a new commercial molecular test for the diagnosis of malignant pleural effusions. The study will: 1) Establish the diagnostic value of the EPISEEK_MPE liquid biopsy assay to identify cancer in pleural effusion and 2) Validate the EPISEEK-MPE liquid biopsy assay for cancer detection in pleural effusion. The long-term goal of this project is to bring the field of pathology a new diagnostic tool for the diagnosis of malignant pleural effusions.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85713
- Recrutamento
- Banner University Medical Center South
-
Contato:
- Trina Hughes
- Número de telefone: 520-626-9372
- E-mail: tdhughes@arizona.edu
-
Tucson, Arizona, Estados Unidos, 85719
- Recrutamento
- Banner University Medical Center Tucson
-
Contato:
- Trina Hughes
- Número de telefone: 520-626-9372
- E-mail: tdhughes@arizona.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adult patients that are having pleural fluid drained as part of clinical care.
Descrição
Inclusion Criteria:
- Adult patients having pleural fluid drained for clinical care (thoracentesis or chest tube placement)
- Consent to have pleural fluid sample used for research
Exclusion Criteria:
- Insufficient fluid available following clinical drainage procedure
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Benign pleural effusions
Patients with pleural effusions due to infection, heart failure, atelectasis, bronchial obstruction, pulmonary embolism, etc. To be included in the benign group, subjects cannot have any cancer-related history within the last 15 years and chest radiograph will be without evidence of lung mass / malignancy. |
|
Indeterminate pleural effusions
Patients with a known cancer diagnosis, but with cytology negative pleural fluid. |
|
Malignant pleural effusions
Patients with known cancer and a cytology positive pleural fluid sample. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Diagnostic performance
Prazo: From enrollment to the completion of the study analysis an average of 2 years
|
To determine the diagnostic performance characteristics of the EPISEEK-MPE test in terms of accuracy, specificity, sensitivity, negative predictive value (NPV), and positive predictive value (PPV). |
From enrollment to the completion of the study analysis an average of 2 years
|
|
Predictive value
Prazo: From enrollment to 1 year post procedure
|
Investigators will evaluate the association of the methylation signal from the EPISEEK-MPE test with overall survival. |
From enrollment to 1 year post procedure
|
|
Validate EPISEEK-MPE
Prazo: From enrollment to the completion of the study analysis
|
Establish the performance specifications of EPISEEK-MPE as a laboratory developed test including:
|
From enrollment to the completion of the study analysis
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Methylation signal
Prazo: At baseline
|
Determine the methylation signal relationship with clinical variables such as age, race, gender, and ethnicity. |
At baseline
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB # 2012283169
- 1R44CA287829-01A1 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
This is an exploratory study with a commercial entity and data is considered joint intellectual property.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .